Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [ 11C](R)-(-)-RWAY

Synapse

Volumn 61, Issue 2, 2007, Pages 96-105

  Liow, Jeih San ^a   Lu, Shuiyu ^a   McCarron, Julie A ^a   Hong, Jinsoo ^a   Musachio, John L ^a   Pike, Victor W ^a   Innis, Robert B ^a   Zoghbi, Sami S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT 1A receptors; 11C (R) ( ) RWAY; CsA; Cyclosporin A; P glycoprotein

Indexed keywords

2,3,4,5,6,7 HEXAHYDRO 1 [4 [1 [4 (2 HYDROXYPHENYL)PIPERAZINYL]] 2 PHENYLBUTYRYL 1H AZEPINE C 11; ARYLBUTYRIC ACID DERIVATIVE; CARBON 11; CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; RADIOLIGAND; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG UPTAKE; EX VIVO STUDY; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; WILD TYPE;

ANIMALS; AZEPINES; BINDING, COMPETITIVE; BLOOD; BRAIN; BRAIN MAPPING; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTORS, SEROTONIN, 5-HT1; TIME FACTORS;

EID: 33845526771     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20348     Document Type: Article

References (29)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug tranporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. 2003. P-glycoprotein: From genomics to mechanism. Oncogene 22:7468-7485.
3. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
4. Doige CA, Ames GFL. 1993. ATP-dependent transport systems in bacteria and humans-Relevance to cystic fibrosis and multidrug resistance. Annu Rev Microbiol 47:291-319.
5. 1A-receptor binding in the brain of cyclic and ovariectomized female rats. J Neuroendocrinol 11:243-249.
6. Gandelman M, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free fraction determination of SPECT radiotracers: β-CIT, IBF, and iomazenil. J Pharm Sci 83:1014-1019.
7. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
8. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112.
9. Ieiri I, Takane H, Otsubo K. 2004. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 43: 553-576. Review.
10. Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC. 2004. Experiment assessment of mass effects in the rat: Implications for small animal PET imaging. Nucl Med Biol 31:771-779.
11. Johnson CA, Seidel J, Vaquero JJ, Pascau J, Desco M, Green MV. 2002. Exact positioning for OSEM reconstructions on the ATLAS depth-of-interaction small animal scanner. Mol Imaging Biol 4: S22 (abstract).
12. Kung MP, Kung HF. 2005. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32:673-678.
13. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K. 2002. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-219.
14. Liow J, Seidel J, Johnson CA, Toyama H, Green MV, Innis RB. 2003. A single slice rebinning/2D exact positioning OSEM reconstruction for the NIH ATLAS small animal PET scanner. J Nucl Med 44:162P (abstract).
15. McCarron JA, Chin FT, Pike VW, Hong J, Musachio JL, Ichise M, Zoghbi SS, Vines DC, Vermeulen ES, Wikstrom HV, Halldin C, Innis RB. 2004. New candidate PET radioligand for brain 5-HT1A receptors based on 2,3,4,5,6,7-hexahydro-1{4- [1[4-(2-methoxyphenyl)-piperazinyl]]-2-phenylbutyryll-1H-azepine (RWAY). Neuroimage 222 (Suppl):T34-T35.
16. Moochala SM, Renton KW. 1986. Inhibition of hepatic microsomal drug metabolism by the immunosuppressive agent cyclosporin A. Biochem Pharmacol 35:1499-1503.
17. 18F]MPPF in rats. Eur J Pharmacol 407:273-280.
18. 11C]Loperamide: A novel and sensitive PET probe for quantification of changes in P-glycoprotein functionality. Mol Imaging Biol 5:121 (abstract).
19. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego: Academic Press.
20. Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinates, 2nd ed. San Diego: Academic Press.
21. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
22. Schinkel AH, Smit JJM, Vantellingen O, Beijnen JH, Wagenaar E, Vandeemter L. Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJ, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
23. Schinkel AH, Wagennar E, Mol CAAM, van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
24. Seidel J, Vaquero JJ, Green MV. 2003. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: Comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Trans Nucl Sci 50:1347-1350.
25. 11C]PE2I. Eur J Nucl Med Mol Imaging (in press).
26. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y. 2006. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-Verapamil. J Nucl Med 47:1427-1433.
27. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
28. 11C]PE2I shows active and inactive radioactive metabolites in rat brain. J Labelled Comp Radiopharm 48:398.
29. 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47: 520-527.